Patent 7462352 was granted and assigned to IMMUNOMEDICS, INC. on December, 2008 by the United States Patent and Trademark Office.
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.